Telos Capital Management Inc. Has $511,000 Position in Illumina, Inc. (NASDAQ:ILMN)

Telos Capital Management Inc. lessened its stake in Illumina, Inc. (NASDAQ:ILMN) by 52.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,671 shares of the life sciences company’s stock after selling 4,101 shares during the period. Telos Capital Management Inc.’s holdings in Illumina were worth $511,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in shares of Illumina in the third quarter valued at approximately $30,000. State of Wyoming acquired a new stake in shares of Illumina in the second quarter valued at approximately $32,000. VisionPoint Advisory Group LLC increased its holdings in shares of Illumina by 344.6% in the third quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock valued at $34,000 after purchasing an additional 193 shares in the last quarter. Riverview Trust Co increased its holdings in shares of Illumina by 203.5% in the third quarter. Riverview Trust Co now owns 261 shares of the life sciences company’s stock valued at $36,000 after purchasing an additional 175 shares in the last quarter. Finally, Gradient Investments LLC increased its holdings in shares of Illumina by 375.0% in the fourth quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock valued at $40,000 after purchasing an additional 225 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Performance

Shares of ILMN stock opened at $118.29 on Thursday. The company has a market capitalization of $18.84 billion, a price-to-earnings ratio of -16.12 and a beta of 1.19. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.29 and a current ratio of 1.66. The company has a 50-day simple moving average of $134.31 and a 200 day simple moving average of $128.15. Illumina, Inc. has a 52 week low of $89.00 and a 52 week high of $232.23.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 8th. The life sciences company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.01 by $0.13. The business had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. Illumina’s revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.14 EPS. On average, sell-side analysts predict that Illumina, Inc. will post 0.91 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. TD Cowen cut shares of Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 price objective on the stock. in a research note on Thursday, January 4th. OTR Global reaffirmed a “mixed” rating on shares of Illumina in a research note on Wednesday, March 20th. Stephens reaffirmed an “overweight” rating and issued a $170.00 price objective on shares of Illumina in a research note on Wednesday, April 10th. HSBC cut shares of Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. Finally, StockNews.com raised shares of Illumina from a “hold” rating to a “buy” rating in a research report on Friday, February 16th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $167.70.

Insider Buying and Selling

In related news, CEO Jacob Thaysen bought 7,330 shares of Illumina stock in a transaction that occurred on Thursday, February 22nd. The stock was acquired at an average price of $135.29 per share, with a total value of $991,675.70. Following the acquisition, the chief executive officer now owns 14,861 shares of the company’s stock, valued at approximately $2,010,544.69. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.17% of the stock is currently owned by insiders.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.